<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785820</url>
  </required_header>
  <id_info>
    <org_study_id>BP42772</org_study_id>
    <secondary_id>2020-004606-60</secondary_id>
    <nct_id>NCT04785820</nct_id>
  </id_info>
  <brief_title>A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus</brief_title>
  <official_title>A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, blinded, active-controlled, global, multicenter study&#xD;
      designed to evaluate the safety and efficacy of RO7121661 and RO7247669, compared with&#xD;
      nivolumab, in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC)&#xD;
      refractory or intolerant to fluoropyrimidine- or taxane- and platinum-based regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">August 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival, Defined as the Time from Randomization to Death from Any Cause</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events, Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), Defined as the Percentage of Participants with a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR), Defined as the Percentage of Participants with an Objective Response or Stable Disease According to RECIST v1.1</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for Participants with ORR, Defined as the Time from the First Occurrence of a Documented Objective Response to Disease Progression According to RECIST v1.1 or Death from any Cause, Whichever Occurs First</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS), Defined as the Time from Randomization to the First Occurrence of Progression as Determined According to RECIST v1.1 or Death from any Cause, Whichever Occurs First</measure>
    <time_frame>Up to 3 years, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Clinically Meaningful Improvement in Global Health Status/Quality of Life (GHS/QoL), and Emotional and Social Functioning, Defined as a ≥10-Point Increase from Baseline as Measured by the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Day 1 of Cycle 1) and Day 1 of Cycles 4, 7, 10, and then every 6 cycles thereafter (each cycle is 14 days) until treatment discontinuation; and every 3 months during the first year of post-treatment follow-up (up to 3 years)</time_frame>
    <description>EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting a Clinically Meaningful Improvement in GHS/QoL, and Emotional and Social Functioning, Defined as a ≥10-Point Increase from Baseline as Measured by the EORTC IL97 Questionnaire</measure>
    <time_frame>Baseline (Cycle 1 Day 1) and Day 1 of Cycles 2, 3, 5, 6, 8, and 9 (each cycle is 14 days)</time_frame>
    <description>EORTC IL97 = European Organisation for Research and Treatment of Cancer - Item Library 97</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting a Clinically Meaningful Improvement in Dysphagia, Defined as a ≥10-Point Increase from Baseline as Measured by the EORTC QLQ-OES18</measure>
    <time_frame>Baseline (Cycle 1 Day 1) and Day 1 of each subsequent treatment cycle (each cycle is 14 days) until treatment discontinuation; and every 3 months during the first year of post-treatment follow-up (up to 3 years)</time_frame>
    <description>EORTC QLQ-OES18 = European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire for Esophageal Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Time-Serum Concentration Curve (AUC) of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentrations of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life of RO7121661, RO7247669, and Nivolumab</measure>
    <time_frame>Predose and at end of infusion on Day 1 of every treatment cycle and on Day 8 of Cycles 1 and 5 (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Drug Antibodies (ADAs) to RO7121661, RO7247669, or Nivolumab at Baseline and During the Study</measure>
    <time_frame>Predose at Baseline (Day 1 of Cycle 1) and on Day 1 of Cycles 2, 3, 4, 5, and 7, and then every 3 cycles thereafter (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of T-cell Subsets by Phenotype and Activation Status (CD4/CD8 HLA-DR+Ki67+) in the Peripheral Blood</measure>
    <time_frame>Predose at Baseline (Day 1 of Cycle 1) and on Day 1 of Cycles 2, 3, 5, and 7, and then every 3 cycles thereafter (each cycle is 14 days); and at treatment discontinuation (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of CD8+ T-cells Infiltrating the Tumor Microenvironment</measure>
    <time_frame>Baseline and Day 1 of Cycle 3 (each cycle is 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of CD8+ T-cells Proliferating (CD8+Ki67+) in the Tumor Microenvironment</measure>
    <time_frame>Baseline and Day 1 of Cycle 3 (each cycle is 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline PDL1, CD8+PD1+, CD8+TIM3+, and CD8+LAG3+ Expression in the Tumor Microenvironment</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Advanced or Metastatic Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>RO7121661</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7247669</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7121661</intervention_name>
    <description>2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.</description>
    <arm_group_label>RO7121661</arm_group_label>
    <other_name>RG7769</other_name>
    <other_name>PD1-TIM3 BsAb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7247669</intervention_name>
    <description>2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.</description>
    <arm_group_label>RO7247669</arm_group_label>
    <other_name>RG6139</other_name>
    <other_name>PD1-LAG3 BsAb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced or metastatic, histologically confirmed esophageal squamous-cell carcinoma&#xD;
             (ESCC)&#xD;
&#xD;
          -  Patients who have previously received 1 line of treatment with either a&#xD;
             fluoropyrimidine- and platinum- or a taxane- and platinum-based regimen in&#xD;
             non-curative intention prior to randomization; or patients who received treatment with&#xD;
             a fluoropyrimidine-/taxane- and platinum-based regimen in curative intention and had&#xD;
             recurrence within 24 weeks after the last dose of the treatment&#xD;
&#xD;
          -  Radiologically measurable disease according to RECIST v1.1. Previously irradiated&#xD;
             lesions should not be counted as target lesions unless clearly progressed after the&#xD;
             radiotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1&#xD;
&#xD;
          -  A life expectancy of at least (≥)12 weeks&#xD;
&#xD;
          -  Tissue samples must be provided for analysis of anti-programmed death ligand-1 (PD-L1)&#xD;
             tumor positivity&#xD;
&#xD;
          -  Adverse events from any prior radiotherapy, chemotherapy, or surgical procedure must&#xD;
             have resolved to Grade ≤1, except alopecia (any grade), vitiligo, endocrinopathy&#xD;
             managed with replacement therapy, and Grade 2 peripheral neuropathy&#xD;
&#xD;
          -  Adequate cardiovascular, hematological, liver, and renal function&#xD;
&#xD;
          -  Serum albumin ≥25 grams per liter (g/L),&#xD;
&#xD;
          -  For participants not receiving therapeutic anticoagulation: prothrombin time (PT) and&#xD;
             activated partial thromboplastin time ≤1.5 times (×) the upper limit of normal (ULN);&#xD;
             for participants receiving therapeutic anticoagulation: stable anticoagulant regimen&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, not a woman of childbearing potential (WOCBP), or a WOCBP who agrees to&#xD;
             remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods&#xD;
             during the treatment period and for at least 5 months after the final dose of study&#xD;
             drug and have a negative pregnancy test (blood) within the 7 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  A male participant must remain abstinent (refrain from heterosexual intercourse) or&#xD;
             use contraceptive measures such as a condom plus an additional contraceptive method&#xD;
             and refrain from donating sperm during the treatment period and for at least 5 months&#xD;
             after the final dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of RO7121661, RO7247669, or nivolumab,&#xD;
             including but not limited to, hypersensitivity to Chinese hamster ovary cell products&#xD;
             or other recombinant human or humanized antibodies&#xD;
&#xD;
          -  Patients with significant malnutrition. Patients whose nutrition has been well&#xD;
             controlled for ≥28 days prior to randomization may be enrolled&#xD;
&#xD;
          -  Evidence of complete esophageal obstruction not amenable to treatment&#xD;
&#xD;
          -  Higher risk of bleeding or fistula caused by esophageal lesions invading adjacent&#xD;
             organs (aorta or tracheobronchial tree)&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             without evidence that disease has been clinically stable for ≥14 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Active or history of carcinomatous meningitis/leptomeningeal disease&#xD;
&#xD;
          -  Asymptomatic CNS primary tumors or metastases if they have requirement for steroids or&#xD;
             enzyme inducing anticonvulsants in the last 28 days prior to randomization&#xD;
&#xD;
          -  Uncontrolled tumor-related pain. Participants requiring pain medication must be on a&#xD;
             stable regimen at study entry&#xD;
&#xD;
          -  Active second malignancy (with some exceptions)&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results, including diabetes&#xD;
             mellitus, history of relevant pulmonary disorders, known autoimmune diseases or immune&#xD;
             deficiency, or other diseases with ongoing fibrosis (such as scleroderma, pulmonary&#xD;
             fibrosis, emphysema, neurofibromatosis, palmar/plantar fibromatosis, etc.).&#xD;
&#xD;
          -  Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed&#xD;
             consent&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular disease within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but&#xD;
             not limited to tuberculosis [TB] and typical mycobacterial disease), parasitic, or&#xD;
             other infection (excluding fungal infections of nail beds) or any major episode of&#xD;
             infection requiring treatment with intravenous (IV) antibiotics or hospitalization&#xD;
             (relating to the completion of the course of antibiotics, except if for tumor fever)&#xD;
             within 28 days prior to randomization&#xD;
&#xD;
          -  Known clinically significant liver disease, including alcoholic hepatitis, cirrhosis,&#xD;
             and inherited liver disease.&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury (excluding biopsies) within&#xD;
             28 days prior to randomization, or anticipation of the need for major surgery during&#xD;
             the course of the study&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the participant at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit informed consent&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (expected to occur once monthly or more frequently)&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) test at screening&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg) or positive total hepatitis B core&#xD;
             antibody (HBcAb) test at screening&#xD;
&#xD;
          -  Positive hepatitis C virus (HCV) antibody test at screening&#xD;
&#xD;
          -  Prior cancer therapy with any immunomodulatory agents including checkpoint inhibitors&#xD;
             (CPIs; such as anti-PDL1/PD1, anti-CTLA-4, anti-LAG3, anti-TIM3)&#xD;
&#xD;
          -  Vaccination with live vaccines within 28 days prior to randomization, or anticipation&#xD;
             that a live attenuated vaccine will be required during the study&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 14 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Concurrent therapy with any other investigational drug (defined as treatment for which&#xD;
             there is currently no regulatory authority approved indication) 28 days or 5&#xD;
             half-lives of the drug (whichever is shorter) prior to randomization&#xD;
&#xD;
          -  Treatment with immune-modulating and immune suppressive agents/medication 5 half-lives&#xD;
             or 28 days (whichever is shorter) prior to randomization&#xD;
&#xD;
          -  Regular immunosuppressive therapy (i.e., for organ transplantation, chronic&#xD;
             rheumatologic disease)&#xD;
&#xD;
          -  Radiotherapy within the last 28 days before start of study drug treatment is not&#xD;
             allowed, with the exception of limited palliative radiotherapy&#xD;
&#xD;
          -  Prior treatment with adoptive cell therapies, such as chimeric antigen receptor T&#xD;
             cells (CAR-T) therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP42772 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masarykův onkologický ústav; Klinika komplexní onkologické péče</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc; Onkologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Onkologisk Afdeling R</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny</name>
      <address>
        <city>Brzozów</city>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK; Poradnia Onkologiczna</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawła II; Oddz. Klin. Chir. Klatki Piersiowej i Onkol.</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NIO im Marii Sklodowskiej-Curie; Klinika Onkologii i Radioterapii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Group of companies &quot;Medci&quot;</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. I.M. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bashkirian Republican Clinical Oncology Dispensary</name>
      <address>
        <city>UFA</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang Hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital; Department of Oncology</name>
      <address>
        <city>Taipei City</city>
        <zip>112201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital; Oncology</name>
      <address>
        <city>Zhongzheng Dist.</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital; Medical Oncology Unit</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital; Department of Oncology</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Ankara Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dicle Uni Medical Faculty; Internal Medicine</name>
      <address>
        <city>Diyarbakir</city>
        <zip>10000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Van Yuzuncu Yil University Hospital; Medical Oncology</name>
      <address>
        <city>Van</city>
        <zip>65000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acıbadem Altunizade Hastanesi; Oncology</name>
      <address>
        <city>Üsküdar</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Kenya</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

